Stock Analyses

Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.

All sectors 6,479 Financial Services 1,900 Healthcare 1,116 Technology 1,079 Industrials 668 Consumer Cyclical 490 Basic Materials 337 Consumer Defensive 248 Communication Services 213 Utilities 183 Energy 165 Real Estate 80

1,116 stocks · page 3 of 19

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

aTYR PHARMA INC

Market implies +81.1%/yr vs model +15.0% · above model

Aurinia Pharmaceuticals Inc.

Deeply undervalued

Discount 60% Return to IV: +152.9%

Market implies +5.5%/yr vs model +25.0% · below model

Aura Biosciences, Inc.

Autolus Therapeutics plc

Market implies +34.2%/yr vs model +15.0% · above model

Aveanna Healthcare Holdings, Inc.

Deeply overvalued

Premium +44% Return to IV: -30.5%

Market implies +12.4%/yr vs model +10.6% · in line

ArriVent BioPharma, Inc.

Atea Pharmaceuticals, Inc.

Market implies -2.4%/yr vs model +15.0% · below model

Avalyn Pharma Inc.

AVANOS MEDICAL, INC.

Deeply overvalued

Premium +172% Return to IV: -63.2%

Owner yield 4.1% 10-yr IRR 6.3% · moderate

Market implies +19.1%/yr vs model +7.4% · above model

Anteris Technologies Global Corp.

Market implies +117.4%/yr vs model +2.0% · above model

Deeply overvalued

Premium +98% Return to IV: -49.5%

Owner yield 6.0% 10-yr IRR 8.3% · steady

Market implies +12.3%/yr vs model +3.0% · above model

Avalo Therapeutics, Inc.

Market implies +142.9%/yr vs model +2.0% · above model

ANAVEX LIFE SCIENCES CORP.

Deeply overvalued

Premium +281% Return to IV: -73.7%

Market implies +13.8%/yr vs model +15.3% · in line

Axsome Therapeutics, Inc.

Market implies +17.9%/yr vs model +15.0% · in line

AYTU BIOPHARMA, INC

Deeply undervalued

Discount 74% Return to IV: +285.3%

Market implies -28.9%/yr vs model +2.0% · below model

ASTRAZENECA PLC

Market implies +50.2%/yr vs model +15.0% · above model

BAXTER INTERNATIONAL INC

Deeply overvalued

Premium +344% Return to IV: -77.5%

Owner yield 6.3% 10-yr IRR 8.9% · steady

Market implies +23.5%/yr vs model +3.0% · above model

BridgeBio Pharma, Inc.

Deeply overvalued

Premium +276% Return to IV: -73.4%

Market implies +18.1%/yr vs model +50.0% · below model

Bone Biologics Corp

Bone Biologics Corp

Beta Bionics, Inc.

Deeply overvalued

Premium +33% Return to IV: -24.5%

Market implies +2.3%/yr vs model +50.0% · below model

BridgeBio Oncology Therapeutics, Inc.

Market implies +68.1%/yr vs model +15.0% · above model

Bicara Therapeutics Inc.

BioCardia, Inc.

Market implies +64.2%/yr vs model +15.0% · above model

Birchtech Corp.

Deeply overvalued

Premium +23% Return to IV: -18.5%

Market implies -2.9%/yr vs model +7.9% · below model

BIOCRYST PHARMACEUTICALS INC

Deeply undervalued

Discount 84% Return to IV: +519.8%

Market implies -6.6%/yr vs model +25.0% · below model

BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp.

BICYCLE THERAPEUTICS PLC

Market implies +19.2%/yr vs model +18.2% · in line

Baird Medical Investment Holdings Ltd

Deeply overvalued

Premium +167% Return to IV: -62.5%

Market implies +7.4%/yr vs model +2.0% · above model

Baird Medical Investment Holdings Ltd

Market implies -37.5%/yr vs model +2.0% · below model

Biodexa Pharmaceuticals Plc

Market implies +150.0%/yr vs model +15.0% · above model

Premium +62% Return to IV: -38.2%

Market implies +1.2%/yr vs model +12.9% · below model

Black Diamond Therapeutics, Inc.

Deeply undervalued

Discount 52% Return to IV: +106.5%

Market implies -6.3%/yr vs model +10.0% · below model

BECTON DICKINSON & CO

Owner yield 5.1% 10-yr IRR 7.7% · steady

Market implies +3.5%/yr vs model +5.4% · in line

Beam Therapeutics Inc.

Market implies +43.2%/yr vs model +28.1% · above model

HeartBeam, Inc.

HeartBeam, Inc.

Butterfly Network, Inc.

Market implies +66.0%/yr vs model +11.8% · above model

BullFrog AI Holdings, Inc.

Market implies +66.4%/yr vs model +15.0% · above model

BullFrog AI Holdings, Inc.

Market implies +31.3%/yr vs model +15.0% · above model

Biofrontera Inc.

Market implies -11.3%/yr vs model +14.8% · below model

Biofrontera Inc.

Market implies -50.0%/yr vs model +14.7% · below model

BioNexus Gene Lab Corp

Discount 22% Return to IV: +28.6%

Market implies -10.9%/yr vs model +2.0% · below model

Market implies -50.0%/yr vs model +2.0% · below model

Bio Green Med Solution, Inc.

Deeply overvalued

Premium +7% Return to IV: -6.3%

Market implies -9.8%/yr vs model +15.0% · below model

Bausch Health Companies Inc.

Deeply undervalued

Discount 87% Return to IV: +684.3%

Owner yield 46.7% 10-yr IRR 60.8% · moderate

Market implies -24.9%/yr vs model +6.5% · below model

BIOHARVEST SCIENCES INC.

Deeply undervalued

Discount 80% Return to IV: +390.2%

Market implies -30.1%/yr vs model +50.0% · below model

Model IV$249.04

Discount 13% Return to IV: +15.6%

Owner yield 6.4% 10-yr IRR 9.1% · steady

Market implies +0.8%/yr vs model +3.0% · in line

BIO-RAD LABORATORIES, INC.

Deeply overvalued

Model IV$254.24

Premium +48% Return to IV: -32.5%

Owner yield 2.9% 10-yr IRR 0.6% · steady

Market implies +9.7%/yr vs model +5.5% · above model

BioAge Labs, Inc.

Market implies +48.7%/yr vs model +15.0% · above model

Bluejay Diagnostics, Inc.

Market implies +2.0%/yr vs model +15.0% · below model